Valuation: Intensity Therapeutics, Inc.

Market Cap 12.67M 11.03M 10.44M 9.49M 17.72M 1.21B 17.81M 124M 48.09M 617M 47.59M 46.53M 1.97B P/E 2026 *
-1.15x
P/E 2027 * -1.83x
Enterprise Value 12.67M 11.03M 10.44M 9.49M 17.72M 1.21B 17.81M 124M 48.09M 617M 47.59M 46.53M 1.97B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.23%
Yield 2026 *
-
Yield 2027 * -
1 day+1.84%
1 week-3.96%
Current month-7.84%
1 month-6.51%
3 months+5.58%
6 months-40.22%
Current year-62.16%
1 week 3.75
Extreme 3.75
4.05
1 month 3.75
Extreme 3.75
5.17
Current year 3.51
Extreme 3.51
11.07
1 year 3.51
Extreme 3.51
43.5
3 years 3.51
Extreme 3.51
286
5 years 3.51
Extreme 3.51
286
10 years 3.51
Extreme 3.51
286
Manager TitleAgeSince
Chief Executive Officer 67 31/03/2012
Director of Finance/CFO 57 10/12/2023
Corporate Officer/Principal - 31/08/2023
Director TitleAgeSince
Chairman 67 31/03/2012
Director/Board Member 60 31/05/2016
Director/Board Member 66 30/04/2018
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Free

Controller/Auditor

11,000 0.4070%
16/07/26 Free

Chief Executive Officer

78,000 2.8859%
16/07/26 Free

Director

5,500 0.2035%
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%-3.96%-35.87%-96.65% 12.67M
+1.23%+1.87%-0.15%+9.57% 46.18B
+0.23%+4.72%+44.32%+27.27% 44.35B
+0.52%-3.15%+349.53%+520.09% 42.21B
+1.55%+3.41%+6.40%+76.45% 40.19B
+1.75%-0.28%+12.42%+41.11% 29.83B
-0.20%+5.49%+23.57%+119.72% 17.17B
-3.49%-8.49% - - 15.7B
+2.92%+8.40%+22.46%+38.87% 15.32B
-2.45%+2.41%-3.16%-35.16% 13.09B
Average +0.39%+1.19%+46.62%+77.92% 26.4B
Weighted average by Cap. +0.60%+1.73%+72.67%+121.17%

Financials

2026 *2027 *
Net sales - -
Net income -11.79M -10.27M -9.72M -8.83M -16.49M -1.13B -16.57M -116M -44.75M -574M -44.28M -43.3M -1.84B -14.93M -13M -12.31M -11.18M -20.89M -1.43B -20.99M -147M -56.68M -727M -56.08M -54.83M -2.33B
Net Debt - -
Logo Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Employees
-
Date Price Change Volume
17/09/26 US$3.880 +1.84% 8,262
16/09/26 US$3.810 0.00% 9,507
15/09/26 US$3.810 -4.27% 3,875
14/09/26 US$3.980 -1.00% 37,197
11/09/26 US$4.020 -0.50% 10,475
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.880USD
Average target price
19.33USD
Spread / Average Target
+398.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INTS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!